Visumab 0.5 mg Injection 1's belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy, and choroidal neovascularization. It is also used to treat retinopathy of prematurity in babies born prematurely.

Visumab 0.5 mg Injection 1's contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist. It binds to VEGF-A (a protein that causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action, and prevents abnormal growth and swelling. It helps stabilise and improve vision.

In some cases, Visumab 0.5 mg Injection 1's may cause side effects such as eye pain, inflammation, retinal bleeding, dry eye, eye irritation, and redness or itching of the eye. Most of these side effects may not require medical attention and resolve over time. However, you are advised to talk to the doctor if any of the side effects persist or worsen.

Let the doctor know if you are allergic to any components in Visumab 0.5 mg Injection 1's. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. Visumab 0.5 mg Injection 1's is not recommended during breastfeeding. Keep your doctor informed about your health condition and medications to rule out any side effects/interactions.

Visumab 0.5 mg Injection 1's belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO), diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), and choroidal neovascularization (CNV). Visumab 0.5 mg Injection 1's contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist, which binds to VEGF-A (a protein which causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action and prevents abnormal growth and swelling. It helps stabilise and improve your vision. This medicine may also be indicated in preterm infants for the treatment of retinopathy of prematurity (ROP).

• Inflammation of the eye
• Retinal bleeding (bleeding in the back of the eye)
• Eye pain
• Bloodshot eye
• Small particles or spots in your vision
• Eye irritation
• Dry eye
• Redness or itching of the eye
• Increased eye pressure

Do not receive Visumab 0.5 mg Injection 1's if you are allergic to any of its components, if you have an infection in or around the eye, severe intraocular inflammation (pain or redness in the eye) or if you are breastfeeding. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. Seek immediate medical attention if you experience worsening eye redness, eye pain or increased discomfort, an increased number of small particles in your vision, blurred or decreased vision, or increased sensitivity to light. Inform the doctor if you have a history of eye conditions, eye treatments, or stroke. Let the doctor know if you are taking any other medicines, including supplements or herbal products.

Drug-Drug Interactions: Inform the doctor if you are using, have recently used or might use any other medicines.

Drug-Food Interactions: No interactions found.

Drug-Disease Interactions: Inform the doctor if you have/had an eye infection, eye inflammation, or stroke.

• Eat a healthy diet and exercise regularly to maintain proper weight.
• Avoid smoking and alcohol consumption.
• Include vegetables, whole grains, and fruits in your diet.
• Get optimal sleep; rest well.

• Women of reproductive potential must use effective contraception during treatment with Visumab 0.5 mg Injection 1's and for 3 months after the last dose.
• Have your eyesight and eye pressure checked as advised by the doctor.

Neovascular (wet) age-related macular degeneration (AMD): AMD is an eye disease that causes vision loss due to a damaged macula. In wet macular degeneration, leaky blood vessels grow under the retina. The key symptom of AMD is blurred vision.

Macular oedema: It occurs when blood vessels leak into the macula (a part of the retina). This causes macula swelling and blurred vision.

Retinal vein occlusion (RVO): RVO is the blockage of small veins that carry blood away from the retina, occurring due to the hardening of arteries or the formation of blood clots. Symptoms include sudden blurring or vision loss.

Diabetic macular oedema (DME): DME is a complication of diabetes that occurs when excess fluid starts to build up in the macula of the eye, leading to vision problems. Symptoms are blurry vision, double vision, seeing floaters, and seeing colours that look washed out.

Proliferative diabetic retinopathy (PDR): It is the advanced stage of diabetic eye disease that occurs when the retina starts growing new blood vessels. Symptoms are vision loss, poor night vision, colours appearing faded or washed out, blurry vision, and seeing an increased number of floaters.

Retinopathy of prematurity (ROP): ROP is a disease-causing vision impairment due to damage to the back of the eye (the retina) caused by abnormal growth of blood vessels.